Some studies show evidence of kidney protection with GLP-1 RA treatment in patients with T2D and CKD; however, the underlying mechanisms and their independence from glycemia remain under investigation [5,86,87,88,89,90]. This evidence concerns the gene GCG and chronic kidney disease.